

Votrient® (pazopanib) - First-time generic

- On October 20, 2023, <u>Sun Pharma</u> and <u>Teva launched</u> <u>AB-rated</u> generic versions of Novartis' Votrient (pazopanib) tablets.
- Votrient is approved for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.